Facebook
Twitter
LinkedIn
Forward
28th University of Chicago Comprehensive Cancer Center Developmental Therapeutics Symposium
Chicago, IL US
May 2, 2025
Don't miss this unique opportunity to deepen your expertise and advance your practice!
Participants at this unique forum will critically analyze data from important clinical studies, engage in thought-provoking discussions on cutting-edge investigational agents in active trials, and delve into the scientific rationale and results of studies featuring novel cancer treatments. Gain actionable insights to seamlessly integrate these innovative therapies into your clinical practice, contribute to the development and success of impactful trials, and strengthen your role as a leader in the oncology community. This activity will empower you with the latest knowledge and tools to effectively implement precision medicine in cancer care, driving improved outcomes for your patients.
For more information, visit the conference website!
Target Audience
This activity is designed for physicians and other healthcare professionals who diagnose, screen, and treat patients with cancer.
Learning Objectives
After this activity, participants will be able to:
- Recall new approaches to pre- and post-FDA approval for dosing and scheduling of anti-cancer agents;
- Recognize the therapeutic ratio of novel agents and approaches to define dose reductions that maintain efficacy;
- State the clinical effects of novel immunotherapeutic agents, including novel checkpoint inhibitors, bispecific antibodies, and novel cellular therapies;
- Identify how to assess patient suitability for participation in ongoing and upcoming cancer clinical trials and projects;
- Cite the relevant pharmacologic and biologic effects of novel anti-cancer agents through the use of blood and tissue samples as well as standard and novel imaging approaches, including novel PET tracer imaging and circulating tumor DNA assays;
- Describe advances in the use of systemic therapies for cancer, including those targeting specific molecular alterations such as DNA repair mutations, specific chromosomal translocations, and tyrosine kinase mutations;
- Assess the status of and developmental pathway for antibody-drug conjugates in solid and hematologic tumors.
You may also be interested in
| Time | Session Title | Speakers |
|---|---|---|
| 8:15 AM - Registration & Breakfast | ||
| 8:45 AM | Welcome | Toyosi Odenike, MD |
| 8:50 AM | The Current Landscape of Novel Therapeutics in Breast Cancer | Nan Chen, MD |
| 9:15 AM | New Frontiers: Personalized Treatment Approaches in Head and Neck Cancer | Ari Rosenberg, MD |
| 9:40 AM | Novel and Emerging Therapies for Small Cell Lung Cancer | Noura Choudhury, MD |
| 10:05 AM - Break | ||
| 10:25 AM | TILs in the Real World: The UChicago Experience With the First FDA-Approved Cell Therapy for a Solid Tumor | Dan Olson, MD |
| 10:50 AM | Prostate Cancer: New Targets Beyond the Androgen Receptor | Mohammad Atiq, MD |
| 11:05 AM | Therapeutic Advances in Hodgkin Lymphoma and Their Impact on Quality of Lifeimizing Cellular Therapy in Lymphoma | Adam DuVall, MD |
| 11:35 AM | Targeted Therapeutics in Acute Leukemia and Myeloid Malignancies | Anand Patel, MD |
| 12:05 PM - Lunch | ||
| 12:20 PM | Concurrent Lunch Breakout: Internal Research Staff & Nurses | Livia Szeto; Sara Mollering; Lauren Wall |
| 12:20 PM | Concurrent Lunch Breakout: Pursuing Organ Preservation for Patients with Locoregionally Advanced Head and Neck Cancer at the University of Chicago | Everett Vokes, MD |
| 1:05 PM - Break | ||
| 1:30 PM | BCMA and Beyond: The Next Generation of Immunotherapies in Multiple Myeloma | Jennifer Cooperrider, MD |
| 1:55 PM | Updates in Novel Therapies for Gynecologic Malignancies | Katherine Kurnit, MD, MPH |
| 2:20 PM | Novel Radiotherapy Approaches to Locally Advanced and Metastatic Malignancies | Aditya Juloori, MD |
| 2:45 PM | Closing Remarks | Toyosi Odenike, MD |
| 2:50 PM | Trainee Post-Conference Reception: Developing a Career in Clinical Research | Toyosi Odenike, MD |
| 3:45 PM - Adjourn | ||
*The agenda is subject to change.
David Rubenstein Forum at the University of Chicago
1201 E 60th St
Chicago, IL
60637
United States
WANT TO KNOW MORE?
Visit the David Rubenstrein Forum's website! For more information about the program, contact Meeting Achievements via e-mail.
The David Rubenstein Forum combines a variety of spaces, both formal and informal, large and small, calm and animated, focused and diffuse, scheduled and spontaneous. Its ten-story tower features vibrant and distinct “neighborhoods.” For example, the third and fourth floors are home to Friedman Hall, a 285-seat auditorium optimized for spoken word, including keynote speeches, invited-speaker addresses, and select performances; these floors and other neighborhoods are connected by a two-story lounge. Meeting rooms on the eighth and ninth floors feature premium furnishings, finishes, and equipment, such as the Peter May Boardroom, a tiered meeting space that seats over 70. The Rubenstein Forum’s unique position on the Midway allows for expansive views toward the campus and surrounding communities as well as downtown Chicago and Lake Michigan.
VISITING CHICAGO
Discover why Condé Nast Traveler readers voted Chicago the Best Big City in the U.S. for a historic eighth year in a row. To help plan your stay in Chicago, visit choosechicago.com.
ACCESSIBILITY The University of Chicago is committed to providing equal access appropriate to need and circumstances and complies fully with legal requirements of the Americans with Disabilities Act. If you are in need of special accommodation, please contact our office at 219-465-1115 or via email at support@meetingachievements.com.
The University of Chicago reserves the right to cancel or postpone this conference due to unforeseen circumstances. In the unlikely event this activity must be cancelled or postponed, the registration fee will be refunded; however, The University of Chicago is not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.
UNIVERSITY OF CHICAGO COURSE DIRECTORS
Walter M. Stadler, MDFred C. Buffett Professor of Medicine and Surgery
Dean for Clinical Research
Senior Advisor to Comprehensive Cancer Center Director
Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credit
University of Chicago Medicine is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Participants who successfully complete the entire activity and complete an evaluation form will earn 5 contact hours.
American Board of Internal Medicine MOC Part II Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Other Participant Credit
Other participants will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
Other participants will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
Please Note: The credit claiming process will close three months after the activity ends. Requests to claim credit after three months will be subject to additional fees.
HOW TO REGISTER
Please log in or create an account to register. Once logged in, select the registration type that best suits you. For help, follow our registration 
guide.
guide.| Profession Type | Fee |
|---|---|
| Physician | $50 |
| Healthcare Professional | $25 |
| Trainee | $25 |
| Industry | $350 |
| CANCELLATION POLICY: If you cancel your participation in this conference, your registration fee less a 50% administrative fee will be refunded when written notification is received by April 2, 2025. No refunds will be made after April 2, 2025. | |
CLAIMING CREDIT
At the end of the activity, the credit-claiming process will unlock. Return to this page and click on "Complete Activity" to proceed.
Please Note: Requests to claim MOC Part II credit must be made within one month to report to ABIM. Requests to claim AMA PRA Category 1 Credit™ after three months will be subject to additional fees.
Please login or create an account to proceed.